JP2024028648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024028648A5 JP2024028648A5 JP2024010098A JP2024010098A JP2024028648A5 JP 2024028648 A5 JP2024028648 A5 JP 2024028648A5 JP 2024010098 A JP2024010098 A JP 2024010098A JP 2024010098 A JP2024010098 A JP 2024010098A JP 2024028648 A5 JP2024028648 A5 JP 2024028648A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- antigenic determinant
- cell according
- hinge
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 21
- 230000000890 antigenic effect Effects 0.000 claims 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 210000005170 neoplastic cell Anatomy 0.000 claims 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 102000054766 genetic haplotypes Human genes 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015904933 | 2015-11-27 | ||
| AU2015904933A AU2015904933A0 (en) | 2015-11-27 | Genetically modified cells and uses thereof | |
| AU2016901328A AU2016901328A0 (en) | 2016-04-11 | Genetically modified cells and uses thereof - III | |
| AU2016901328 | 2016-04-11 | ||
| JP2018546725A JP6976960B2 (ja) | 2015-11-27 | 2016-11-23 | 遺伝子改変された細胞およびその使用 |
| PCT/AU2016/051141 WO2017088012A1 (en) | 2015-11-27 | 2016-11-23 | Genetically modified cells and uses thereof |
| JP2021183110A JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183110A Division JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024028648A JP2024028648A (ja) | 2024-03-04 |
| JP2024028648A5 true JP2024028648A5 (enExample) | 2024-07-18 |
Family
ID=58762790
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546725A Active JP6976960B2 (ja) | 2015-11-27 | 2016-11-23 | 遺伝子改変された細胞およびその使用 |
| JP2021183110A Pending JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
| JP2024010098A Pending JP2024028648A (ja) | 2015-11-27 | 2024-01-26 | 遺伝子改変された細胞およびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546725A Active JP6976960B2 (ja) | 2015-11-27 | 2016-11-23 | 遺伝子改変された細胞およびその使用 |
| JP2021183110A Pending JP2022027762A (ja) | 2015-11-27 | 2021-11-10 | 遺伝子改変された細胞およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11400145B2 (enExample) |
| EP (3) | EP3380117B1 (enExample) |
| JP (3) | JP6976960B2 (enExample) |
| CN (2) | CN116121281A (enExample) |
| AU (2) | AU2016361451B2 (enExample) |
| CA (1) | CA3004120A1 (enExample) |
| ES (2) | ES2862907T3 (enExample) |
| IL (2) | IL296410A (enExample) |
| MY (1) | MY189819A (enExample) |
| SG (2) | SG11201803493UA (enExample) |
| WO (1) | WO2017088012A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| EP4353750A3 (en) * | 2016-06-24 | 2024-07-24 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| CA3035660A1 (en) | 2016-09-06 | 2018-03-15 | The Children's Medical Center Corporation | Immune cells derived from induced pluripotent stem cell |
| EP3595706A1 (en) | 2017-03-17 | 2020-01-22 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| JP7457642B2 (ja) | 2017-04-03 | 2024-03-28 | ビオンテック ユーエス インコーポレイテッド | タンパク質抗原およびその使用 |
| MX2019011897A (es) * | 2017-04-18 | 2019-11-28 | Fujifilm Cellular Dynamics Inc | Celulas efectoras inmunitarias especificas de antigenos. |
| AU2018352984B2 (en) * | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CN109971721B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 自表达cd47抗体的间皮素特异性car-t细胞及其用途 |
| CN109971716B (zh) * | 2017-12-28 | 2023-08-01 | 上海细胞治疗研究院 | 自分泌cd47抗体的egfr特异性car-t细胞及其用途 |
| SG11202007622SA (en) * | 2018-02-11 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| AU2019225393A1 (en) | 2018-02-23 | 2020-08-20 | Cartherics Pty. Ltd. | T cell disease treatment targeting TAG-72 |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| GB201807945D0 (en) | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Vector production |
| JP2022516389A (ja) * | 2018-05-31 | 2022-02-28 | ワシントン・ユニバーシティ | 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| KR20210040396A (ko) * | 2018-08-01 | 2021-04-13 | 시티 오브 호프 | Tag72-양성 종양의 치료를 위한, tag72 표적화된 키메라 항원 수용체 변형된 t 세포 |
| WO2020252303A1 (en) * | 2019-06-12 | 2020-12-17 | The Regents Of The University Of California | Engineered off-the-shelf immune cells and methods of use thereof |
| AR120538A1 (es) | 2019-11-25 | 2022-02-23 | Univ Kyoto | Banco de células maestras de células t |
| BR112022023371A2 (pt) * | 2020-05-22 | 2022-12-20 | Chongqing Prec Biotech Co Ltd | Proteína de fusão para reversão do microambiente tumoral, vetor de expressão, célula imune, receptor de antígeno quimérico resistente à imunossupressão tumoral, sequência de ácido nucleico, método para preparar uma célula imune, composição farmacêutica, e, uso da composição farmacêutica |
| EP4161536A4 (en) | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN117441010A (zh) * | 2021-04-07 | 2024-01-23 | 世纪治疗股份有限公司 | 从诱导多能干细胞产生α-βT细胞的组合物和方法 |
| WO2023110824A1 (en) * | 2021-12-15 | 2023-06-22 | Novo Nordisk A/S | Novel integrin associated protein (iap) |
| CN114573710A (zh) * | 2022-02-16 | 2022-06-03 | 南方医科大学珠江医院 | 一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用 |
| WO2024036214A2 (en) * | 2022-08-10 | 2024-02-15 | Jasper Therapeutics, Inc. | Modified stem cell compositions and methods for use |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| AU744160B2 (en) * | 1996-10-25 | 2002-02-14 | Cell Genesys, Inc. | Targeted cytolysis of cancer cells |
| US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| AU774876B2 (en) | 1999-06-29 | 2004-07-08 | Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
| US6761883B2 (en) | 1999-06-29 | 2004-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| DE10130800B4 (de) | 2001-06-22 | 2005-06-23 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP1530418A4 (en) | 2002-05-31 | 2005-10-12 | Univ Leland Stanford Junior | METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS |
| US7592174B2 (en) | 2002-05-31 | 2009-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation of mesenchymal stem cells |
| WO2004024875A2 (en) | 2002-09-13 | 2004-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian megakaryocyte progenitor cell |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7589181B2 (en) * | 2003-08-29 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use |
| AU2004279742A1 (en) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| WO2005057172A2 (en) | 2003-12-05 | 2005-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Identification, isolation and elimination of cancer stem cells |
| US7749754B2 (en) | 2004-06-09 | 2010-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and characterization of muscle regenerating cells |
| US7641897B2 (en) | 2004-11-23 | 2010-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Feeder layer and serum independent embryonic stem cells |
| WO2006089218A2 (en) | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating angiogenesis |
| WO2006116076A2 (en) * | 2005-04-28 | 2006-11-02 | Genencor International, Inc. | Tab molecules |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| CA3163418A1 (en) | 2006-10-06 | 2008-05-22 | Jeffrey S. Isenberg | Prevention of tissue ischemia, related methods and compositions |
| US7767410B2 (en) | 2006-12-07 | 2010-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| US7781179B2 (en) | 2006-12-07 | 2010-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of transitional cell carcinoma stem cells |
| US8765390B2 (en) | 2006-12-08 | 2014-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of squamous carcinoma stem cells |
| PT4160212T (pt) | 2008-01-15 | 2024-06-25 | Univ Leland Stanford Junior | Marcadores de células estaminais de leucemia mielóide aguda |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| DK2279253T3 (en) | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| US8320687B2 (en) | 2009-02-05 | 2012-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Universal lossy compression methods |
| CN103087991B (zh) * | 2009-06-05 | 2018-06-12 | 富士胶片细胞动力公司 | 重编程t细胞和造血细胞的方法 |
| US9290577B2 (en) * | 2009-07-03 | 2016-03-22 | Avipep Pty Limited | Immuno-conjugates and methods for producing them |
| CA2771336C (en) | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| US9151760B2 (en) | 2009-09-29 | 2015-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| WO2011094538A1 (en) | 2010-01-29 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Depletion of teratoma-forming pluripotent stem cells |
| HRP20170254T1 (hr) | 2010-05-14 | 2017-04-21 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 |
| US9212229B2 (en) * | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| JP6082997B2 (ja) * | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| ES2778701T3 (es) | 2012-07-13 | 2020-08-11 | The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer | Gestión de toxicidad para la actividad antitumoral de CAR |
| CN104583230A (zh) | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | 通过共同引入双特异性抗体增强car t细胞的活性 |
| US9045734B2 (en) | 2012-07-31 | 2015-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and characterization of progenitor cells from mesothelium |
| UA128182C2 (uk) | 2012-11-13 | 2024-05-01 | Біонтех Аґ | Агенти для лікування експресуючих клаудин ракових захворювань |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| DK2981607T3 (da) | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller |
| AU2014342020C1 (en) * | 2013-10-31 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof |
| ES2792849T3 (es) * | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| US20180214527A1 (en) * | 2015-03-26 | 2018-08-02 | City Of Hope | Bi-specific targeted chimeric antigen receptor t cells |
| KR20250141836A (ko) * | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| CN105331586B (zh) | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
-
2016
- 2016-11-23 WO PCT/AU2016/051141 patent/WO2017088012A1/en not_active Ceased
- 2016-11-23 EP EP16867445.5A patent/EP3380117B1/en active Active
- 2016-11-23 SG SG11201803493UA patent/SG11201803493UA/en unknown
- 2016-11-23 ES ES16867445T patent/ES2862907T3/es active Active
- 2016-11-23 ES ES20169645T patent/ES2988976T3/es active Active
- 2016-11-23 EP EP20169645.7A patent/EP3708587B1/en active Active
- 2016-11-23 CA CA3004120A patent/CA3004120A1/en active Pending
- 2016-11-23 US US15/778,836 patent/US11400145B2/en active Active
- 2016-11-23 CN CN202211541314.3A patent/CN116121281A/zh active Pending
- 2016-11-23 AU AU2016361451A patent/AU2016361451B2/en active Active
- 2016-11-23 JP JP2018546725A patent/JP6976960B2/ja active Active
- 2016-11-23 IL IL296410A patent/IL296410A/en unknown
- 2016-11-23 EP EP20169648.1A patent/EP3708588A1/en active Pending
- 2016-11-23 MY MYPI2018701648A patent/MY189819A/en unknown
- 2016-11-23 CN CN201680069543.6A patent/CN109152824B/zh active Active
- 2016-11-23 SG SG10201912825XA patent/SG10201912825XA/en unknown
-
2018
- 2018-05-24 IL IL259586A patent/IL259586B2/en unknown
-
2021
- 2021-11-10 JP JP2021183110A patent/JP2022027762A/ja active Pending
-
2022
- 2022-06-09 US US17/836,052 patent/US20220305106A1/en not_active Abandoned
-
2024
- 2024-01-08 AU AU2024200108A patent/AU2024200108A1/en active Pending
- 2024-01-26 JP JP2024010098A patent/JP2024028648A/ja active Pending
-
2025
- 2025-07-17 US US19/271,861 patent/US20250340612A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024028648A5 (enExample) | ||
| JP2022027762A5 (enExample) | ||
| JP2021177771A5 (enExample) | ||
| JP2018535701A5 (enExample) | ||
| JP2023071729A5 (enExample) | ||
| JP2023134735A5 (enExample) | ||
| JP2020533958A5 (enExample) | ||
| JP2018532407A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2018504459A5 (enExample) | ||
| JP2020529841A5 (enExample) | ||
| JP2016514457A5 (enExample) | ||
| JP2021500881A5 (enExample) | ||
| JP2020519298A5 (enExample) | ||
| JP2013063981A5 (enExample) | ||
| JP2018531014A5 (enExample) | ||
| JP2020513844A5 (enExample) | ||
| RU2016124280A (ru) | Клетка | |
| JPWO2020061498A5 (enExample) | ||
| JP2019530441A5 (enExample) | ||
| JPWO2020228824A5 (enExample) | ||
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| Moesta et al. | Chimpanzees use more varied receptors and ligands than humans for inhibitory killer cell Ig-like receptor recognition of the MHC-C1 and MHC-C2 epitopes | |
| JPWO2020228825A5 (enExample) | ||
| JPWO2020069184A5 (enExample) |